Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BLK (B lymphocyte kinase) is a non-receptor tyrosine kinase belonging to the Src family of proto-oncogenes. It is primarily expressed in B-lineage cells and plays a significant role in B-cell receptor (BCR) signaling and B-cell development. The protein encoded by the BLK gene is involved in cell proliferation and differentiation, particularly within the immune system. Activation of BLK leads to downstream phosphorylation events that are critical for further signal propagation within the cell. While direct disease associations specific to BLK mutations or dysregulation remain less well characterized compared with some other Src-family members, aberrant activity or altered expression could theoretically contribute to disorders involving abnormal proliferation/differentiation of lymphoid lineages.
Kinase inhibition (potential, not explicitly stated for specific BLK inhibitors in the text, but inferred from general Src family kinase targeting)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BLK proto-oncogene, Src family tyrosine kinase (BLK).